Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Miguel Abal is active.

Publication


Featured researches published by Miguel Abal.


The Journal of Steroid Biochemistry and Molecular Biology | 2008

Novel molecular profiles of endometrial cancer-new light through old windows.

Andreas Doll; Miguel Abal; Marina Rigau; Marta Monge; M. González; Santiago Demajo; E. Colás; Marta Llauradó; H. Alazzouzi; J. Planagumá; M.A. Lohmann; J. Garcia; S. Castellvi; J. Ramon y Cajal; Jordi Xercavins; Francesc Alameda; J. Reventós

Endometrial carcinoma (EC) is the most common gynecological malignancy in the western world. A widely accepted dualistic model, which has been established on a morphological basis, differentiates EC into two broad categories: Type I oestrogen-dependent adenocarcinoma with an endometrioid morphology and Type II non-oestrogen-dependent EC with a serous papillary or clear cell morphology. Molecular genetic evidence indicates that endometrial carcinoma, as described in other malignancies, likely develops as the result of a stepwise accumulation of alterations in cellular regulatory pathways, such as oncogene activation and tumor suppressor gene inactivation, which lead to dysfunctional cell growth. These molecular alterations appear to be specific in Type I and Type II cancers. In type I endometrioid endometrial cancer, PTEN gene silencing in conjunction with defects in DNA mismatch repair genes, as evidenced by the microsatellite instability phenotype, or mutations in the K-ras and/or beta-catenin genes, are recognized major alterations, which define the progression of the normal endometrium to hyperplasia, to endometrial intraepithelial neoplasia, and then on to carcinoma. In contrast, Type II cancers show mutations of TP53 and Her-2/neu and seem to arise from a background of atrophic endometrium. Nevertheless, despite the great effort made to establish a molecularly-based histological classification, the following issues must still be clarified: what triggers the tumor cells to invade the myometrium and what causes vascular or lymphatic dissemination, finally culminating in metastasis? RUNX1, a transcription factor, was recently identified as one of the most highly over-expressed genes in a microarray study of invasive endometrial carcinoma. Another candidate gene, which may be associated with an initial switch to myometrial infiltration, is the transcription factor ETV5/ERM. These studies, as well as those conducted for other genes possibly involved in the mitotic checkpoint as a major mechanism of carcinogenesis in non-endometrioid endometrial cancer, could help in understanding the differences in the biology and the clinical outcome among histological types.


Oncogene | 2013

Endometrial carcinoma: molecular alterations involved in tumor development and progression

Gema Moreno-Bueno; Xavier Dolcet; L Catasus; Miguel Abal; Eva Colas; Jaume Reventós; José Palacios; Jaime Prat; Xavier Matias-Guiu

In the western world, endometrial carcinoma (EC) is the most common cancer of the female genital tract. The annual incidence has been estimated at 10–20 per 100 000 women. Two clinicopathological variants are recognized: the estrogen related (type I, endometrioid) and the non-estrogen related (type II, non-endometrioid).The clinicopathological differences are paralleled by specific genetic alterations, with type I showing microsatellite instability and mutations in phosphatase and tensin homologue deleted on chromosome 10, PIK3CA, K-RAS and CTNNB1 (β-catenin), and type II exhibiting TP53 mutations and chromosomal instability. Some non-endometrioid carcinomas probably arise from pre-existing endometrioid carcinomas as a result of tumor progression and, not surprisingly, some tumors exhibit combined or mixed features at the clinical, pathological and molecular levels. In EC, apoptosis resistance may have a role in tumor progression. Understanding pathogenesis at the molecular level is essential in identifying biomarkers for successful targeted therapies. In this review, the genetic changes of endometrial carcinogenesis are discussed in the light of the morphological features of the tumors and their precursors.


Cancer Research | 2004

A Differential Gene Expression Profile Reveals Overexpression of RUNX1/AML1 in Invasive Endometrioid Carcinoma

Jesús Planagumà; María Díaz-Fuertes; Miguel Abal; Marta Monge; Ángel García; Teresa Baró; Timothy M. Thomson; Jordi Xercavins; Francesc Alameda; Jaume Reventós

Endometrial carcinoma is the most common gynecological malignant disease in industrialized countries. Two clinicopathological types of endometrial carcinoma have been described, based on estrogen relation and grade: endometrioid carcinoma (EEC) and non-EEC (NEEC). Some of the molecular events that occur during the development of endometrial carcinoma have been characterized, showing a dualistic genetic model for EEC and NEEC. However, the molecular bases for endometrial tumorigenesis are not clearly elucidated. In the present work, we attempted to identify new genes that could trigger cell transformation in EEC. We analyzed the differential gene expression profile between tumoral and nontumoral endometrial specimens with cDNA array hybridization. Among the 53 genes for which expression was found to be altered in EEC, the acute myeloid leukemia proto-oncogene, RUNX1/AML1, was one of the most highly up-regulated. The gene expression levels of RUNX1/AML1 were quantified by real-time quantitative PCR, and protein levels were characterized by tissue array immunohistochemistry. Real-time quantitative PCR validated RUNX1/AML1 up-regulation in EEC and demonstrated a specific and significantly stronger up-regulation in those tumor stages associated with myometrial invasion. Furthermore, tissue array immunohistochemistry showed that RUNX1/AML1 up-regulation correlates to the process of tumorigenesis, from normal atrophic endometrium to simple and complex hyperplasia and then, on to carcinoma. These results demonstrate for the first time the up-regulation of RUNX1/AML1 in EEC correlating with the initial steps of myometrial infiltration.


PLOS ONE | 2012

Molecular Characterization of Circulating Tumor Cells in Human Metastatic Colorectal Cancer

Jorge Barbazán; Lorena Alonso-Alconada; Laura Muinelo-Romay; María Vieito; Alicia Abalo; Marta Alonso-Nocelo; Sonia Candamio; Elena Gallardo; Beatriz Malvar Fernandez; Ihab Abdulkader; María de los Ángeles Casares; Antonio Gómez-Tato; Rafael Lopez-Lopez; Miguel Abal

Metastatic colorectal cancer (mCRC) relies on the detachment of aggressive malignant cells from the primary tumor into the bloodstream and, concordantly, the presence of these Circulating Tumor Cells (CTC) is associated with a poor prognosis. In this work, the molecular characterization of CTC from mCRC patients was approached, with the aim of understanding their biology and improving their clinical utility in the management of colorectal cancer patients. For this, EpCAM-based immunoisolation of CTC was combined with whole transcriptome amplification and hybridization onto cDNA microarrays. Gene expression data from mCRC patients, once the background of unspecific immunoisolation from a group of controls had been subtracted, resulted in 410 genes that characterized the CTC population. Bioinformatics were used for the biological interpretation of the data, revealing that CTC are characterized by genes related to cell movement and adhesion, cell death and proliferation, and cell signalling and interaction. RTqPCR on an independent series of mCRC patients and controls was used for the validation of a number of genes related to the main cellular functions characterizing the CTC population. Comparison between primary carcinomas and lung and liver metastases further involved the CTC-genes in the promotion of metastasis. Moreover, the correlation of CTC-gene expression with clinical parameters demonstrated detection and prognosis significance. In conclusion, the molecular characterization of CTC from mCRC patients and the identification of diagnostic and prognostic biomarkers represent an innovative and promising approach in the clinical management of this type of patients.


Clinical & Translational Oncology | 2012

The EMT signaling pathways in endometrial carcinoma.

Eva Colas; Nuria Pedrola; Laura Devis; Tugçe Ertekin; Irene Campoy; Elena Martínez; Marta Llauradó; Marina Rigau; Mireia Olivan; Marta Rizo García; Silvia Cabrera; Jordi Xercavins; Josep Castellví; Ángel García; Santiago Ramón y Cajal; Gema Moreno-Bueno; Xavier Dolcet; Francesc Alameda; José Palacios; Jaime Prat; Andreas Doll; Xavier Matias-Guiu; Miguel Abal; Jaume Reventós

Endometrial cancer (EC) is the most common gynecologic malignancy of the female genital tract and the fourth most common neoplasia in women. In EC, myometrial invasion is considered one of the most important prognostic factors. For this process to occur, epithelial tumor cells need to undergo an epithelial to mesenchymal transition (EMT), either transiently or stably, and to differing degrees. This process has been extensively described in other types of cancer but has been poorly studied in EC. In this review, several features of EMT and the main molecular pathways responsible for triggering this process are investigated in relation to EC. The most common hallmarks of EMT have been found in EC, either at the level of E-cadherin loss or at the induction of its repressors, as well as other molecular alterations consistent with the mesenchymal phenotype-like L1CAM and BMI-1 up-regulation. Pathways including progesterone receptor, TGFβ, ETV5 and microRNAs are deeply related to the EMT process in EC.


International Journal of Cancer | 2011

Molecular markers of endometrial carcinoma detected in uterine aspirates.

Eva Colas; Cristina Fernández Pérez; Silvia Cabrera; Nuria Pedrola; Marta Monge; Josep Castellví; Fernando Eyzaguirre; Jesus Gregorio; Anna Ruiz; Marta Llauradó; Marina Rigau; Marta Garcia; Tugçe Ertekin; Melania Montes; Rafael Lopez-Lopez; Ramon Carreras; Jordi Xercavins; Alicia Ortega; Tamara Maes; Elisabet Rosell; Andreas Doll; Miguel Abal; Jaume Reventós

Endometrial cancer (EC) is the most frequent of the invasive tumors of the female genital tract. Although usually detected in its initial stages, a 20% of the patients present with advanced disease. To date, no characterized molecular marker has been validated for the diagnosis of EC. In addition, new methods for prognosis and classification of EC are needed to combat this deadly disease. We thus aimed to identify new molecular markers of EC and to evaluate their validity on endometrial aspirates. Gene expression screening on 52 carcinoma samples and series of real‐time quantitative PCR validation on 19 paired carcinomas and normal tissue samples and on 50 carcinoma and noncarcinoma uterine aspirates were performed to identify and validate potential biomarkers of EC. Candidate markers were further confirmed at the protein level by immunohistochemistry and Western blot. We identified ACAA1, AP1M2, CGN, DDR1, EPS8L2, FASTKD1, GMIP, IKBKE, P2RX4, P4HB, PHKG2, PPFIBP2, PPP1R16A, RASSF7, RNF183, SIRT6, TJP3, EFEMP2, SOCS2 and DCN as differentially expressed in ECs. Furthermore, the differential expression of these biomarkers in primary endometrial tumors is correlated to their expression level in corresponding uterine fluid samples. Finally, these biomarkers significantly identified EC with area under the receiver‐operating‐characteristic values ranging from 0.74 to 0.95 in uterine aspirates. Interestingly, analogous values were found among initial stages. We present the discovery of molecular biomarkers of EC and describe their utility in uterine aspirates. These findings represent the basis for the development of a highly sensitive and specific minimally invasive method for screening ECs.


Oncogene | 2004

Enhanced sensitivity to irinotecan by Cdk1 inhibition in the p53-deficient HT29 human colon cancer cell line

Miguel Abal; Rui Bras-Gonçalves; Jean-Gabriel Judde; Hafida Fsihi; Patricia de Cremoux; Daniel Louvard; Henri Magdelenat; Sylvie Robine; Marie-France Poupon

Mutations in the tumor-suppressor gene p53 have been associated with advanced colorectal cancer (CRC). Irinotecan (CPT-11), a DNA topoisomerase 1 inhibitor, has been recently incorporated to the adjuvant therapy. Since the DNA-damage checkpoint depends on p53 activation, the status of p53 might critically influence the response to CPT-11. We analysed the sensitivity to CPT-11 in the human colon cancer cell line HT29 (mut p53) and its wild-type (wt)-p53 stably transfected subclone HT29-A4. Cell-cycle analysis in synchronised cells demonstrated the activation of transfected wt-p53 and a p21WAF1/CIP1-dependent cell-cycle blockage in the S phase. Activated wt-p53 increased apoptosis and enhanced sensitivity to CPT-11. In p53-deficient cells, cDNA-macroarray analysis and western blotting showed an accumulation of the cyclin-dependent kinase (cdk)1/cyclin B complex. Subsequent p53-independent activation of the cdk-inhibitor (cdk-I) p21WAF1/CIP1 prevented cell-cycle progression. Cdk1 induction was exploited in vivo to improve the sensitivity to CPT-11 by additional treatment with the cdk-I CYC-202. We demonstrate a gain of sensitivity to CPT-11 in a p53-mutated colon cancer model either by restoring wild-type p53 function or by sequential treatment with cdk-Is. Considering that mutations in p53 are among the most common genetic alterations in CRC, a therapeutic approach specifically targeting p53-deficient tumors could greatly improve the treatment outcomes.


Molecular and Cellular Endocrinology | 2012

Molecular bases of endometrial cancer: New roles for new actors in the diagnosis and the therapy of the disease

Marta Llauradó; Anna Ruiz; Blanca Majem; Tugçe Ertekin; Eva Colas; Nuria Pedrola; Laura Devis; Marina Rigau; Tamara Sequeiros; Melania Montes; Marta Garcia; Silvia Cabrera; Jordi Xercavins; Josep Castellví; Ángel García; Santiago Ramón y Cajal; Gema Moreno; Francesc Alameda; Mónica H. Vazquez-Levin; José Palacios; Jaime Prat; Andreas Doll; Xavier Matias-Guiu; Miguel Abal; Jaume Reventós

Endometrial carcinoma (EC) is the most commonly diagnosed gynecologic malignancy in the western world. The majority of these cancers are curable, but a subset about 15-20% of endometrial tumors exhibits an aggressive phenotype. Based on clinic-pathological and molecular characteristics, EC has been classified into two groups: Type I estrogen-dependent adenocarcinomas, which have a good prognosis and an endometrioid histology, and Type II or non-estrogen-dependent EC associated with poor prognosis and non-endometrioid histology. EC develops as a result of a stepwise accumulation of alterations that seem to be specific of each histological type. However, more knowledge is needed to better understand the differences in the biology and the clinical outcome of EC. We would like to highlight the need to explore new potential biomarkers of EC as a tool for the detection and monitoring of aggressive endometrial tumors that, at the same time, will allow us to develop novel and more selective molecular targeted therapies against EC.


Biology of the Cell | 2005

Centrioles resist forces applied on centrosomes during G2/M transition

Miguel Abal; Guy Keryer; Michel Bornens

Background information. Centrosome movements at the onset of mitosis result from a balance between the pulling and pushing forces mediated by microtubules. The structural stability of the centrosome core structure, the centriole pair, is correlated with a heavy polyglutamylation of centriole tubulin.


Carcinogenesis | 2009

Proteomic approach to ETV5 during endometrial carcinoma invasion reveals a link to oxidative stress

Marta Monge; Eva Colas; Andreas Doll; Josep Castellví; Berta Diaz; Marta de la Cuesta González; Rafael Lopez-Lopez; Jordi Xercavins; Ramon Carreras; Francesc Alameda; Francesc Canals; Franco Gabrielli; Jaume Reventós; Miguel Abal

Endometrial cancer, the most common gynecological malignancy in western countries, is characterized by a favorable prognosis. Nonetheless, deep myometrial invasion correlates with more undifferentiated tumors, lymph-vascular invasion, node involvement and decreased global survival. We have described previously the Ets family member ERM/ETV5 specifically upregulated in endometrial endometrioid carcinoma (EEC) associated with myometrial infiltration. To understand the role of this transcription factor during myometrial infiltration, we analyzed by two-dimension differential gel electrophoresis (2D-DIGE) technology those proteins whose expression was altered in endometrial cell lines stably overexpressing ERM/ETV5. Pathway analysis pointed to actin regulation and transforming growth factor beta and progesterone signaling as processes regulated by ERM/ETV5. In addition, we characterized the specific upregulation of the nuclear dehydrogenase/reductase Hep27 as well as its ERM/ETV5-dependent mitochondrial localization. Further functional studies demonstrated a protective role of Hep 27 against apoptosis induced by oxidative stress. Overall, the ETV5-related proteomic approach performed in the Hec-1A cell line reinforces a role of this transcription factor in the regulation of the migratory and invasive tumor behavior and points to a modulated response to oxidative stress associated with the promotion of invasion in endometrial cancer. Unraveling the molecular events in EEC associated with the initiation of tumor invasion would represent an obvious improvement in the pursuit of rational targets for the onset of metastasis. This knowledge would also be a valuable tool for the molecular stratification of patients since myometrial affectation determines an increase in the rate of recurrence after a first surgical treatment and a decrease in 5 year survival.

Collaboration


Dive into the Miguel Abal's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Rafael Lopez-Lopez

Group Health Research Institute

View shared research outputs
Top Co-Authors

Avatar

Eva Colas

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Laura Muinelo-Romay

Instituto de Salud Carlos III

View shared research outputs
Top Co-Authors

Avatar

Francesc Alameda

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Jordi Xercavins

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Marta Monge

Autonomous University of Barcelona

View shared research outputs
Top Co-Authors

Avatar

Xavier Matias-Guiu

Hospital Universitari Arnau de Vilanova

View shared research outputs
Top Co-Authors

Avatar

Marta Llauradó

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Ángel García

Autonomous University of Barcelona

View shared research outputs
Researchain Logo
Decentralizing Knowledge